Search for: "Solvay Pharmaceuticals Inc" Results 1 - 20 of 50
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 Dec 2015, 9:00 am
The case was originally filed on June 10, 2003, by relators John King and Tammy Drummond, naming several pharmaceutical companies as defendants including Solvay Pharmaceuticals Inc. [read post]
22 Dec 2015, 9:00 am
The case was originally filed on June 10, 2003, by relators John King and Tammy Drummond, naming several pharmaceutical companies as defendants including Solvay Pharmaceuticals Inc. [read post]
22 Dec 2015, 9:00 am
The case was originally filed on June 10, 2003, by relators John King and Tammy Drummond, naming several pharmaceutical companies as defendants including Solvay Pharmaceuticals Inc. [read post]
7 Dec 2009, 3:57 am by Mara Zimmerman
The relators were former sales representatives at Solvay Pharmaceuticals and alleged that Solvay had established an off-label marketing campaign for a prescription drug used to treat AIDS and cancer patients. [read post]
18 Oct 2009, 5:42 pm
  Judge Brown found that the patent in question, US Patent No. 5,565,473, was valid and enforceable, and [...]...FTC Sues Regarding AndroGel Patent Settlement The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to… [read post]
11 Apr 2013, 4:57 am by Eric Guttag
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of… [read post]
16 Oct 2006, 7:58 pm
Solvay Pharmaceuticals settled patent litigation with generic drug makers Par Pharmaceutical Cos. and Watson Pharmaceuticals Inc. over Solvay's AndroGel drug product. [read post]
28 May 2014, 10:31 am by Don T. Hibner, Jr.
In April 1999, Solvay Pharmaceuticals, LLC (“Solvay”) filed a New Drug Application (“NDA”) with the Food and Drug Administration (“FDA”) seeking approval to commercially market a testosterone replacement gel (“AndroGel”). [read post]
26 Jun 2013, 5:30 am by RatnerPrestia
The patentee, Solvay Pharmaceuticals, agreed to license various generic challengers of its patent for a testosterone supplement, AndroGel, which would have permitted the challengers to enter the market at a future date but prior to patent expiry. [read post]
2 Dec 2009, 11:05 am by dbmadmin
On December 2, 2009, the FTC announced an order settling charges that Watson Pharmaceuticals, Inc. [read post]
25 Jun 2013, 6:52 am
Back in 1999, Solvay Pharmaceuticals had filed a New Drug Application for a drug named AndroGel. [read post]
24 Nov 2009, 1:11 am by Greg Jones
Other defendants named in the MDL include Bristol-Myers Squibb Co., Solvay Pharmaceuticals Inc., Watson Pharmaceuticals Inc. and Ortho-McNeil Janssen Pharmaceuticals Inc. [read post]
24 Nov 2009, 1:11 am by Greg Jones
Other defendants named in the MDL include Bristol-Myers Squibb Co., Solvay Pharmaceuticals Inc., Watson Pharmaceuticals Inc. and Ortho-McNeil Janssen Pharmaceuticals Inc. [read post]
13 Nov 2008, 5:27 pm
  The Supreme Court's 2004 decision in Verizon Communications Inc. v. [read post]
23 Oct 2012, 6:30 am by Matthew Gilpin
Watson Pharmaceuticals, Inc.[6] The petition seeks to overturn the Eleventh Circuit’s dismissal of the FTC’s challenge to a reverse payment settlement agreement between Solvay Pharmaceuticals, Inc., and several generic manufacturers over a drug called Androgel. [read post]